Evdi Injection, Solution, Concentrate
NDC 60505-6423
Product Information
Evdi (trabectedin) is a NDA-approved product labeled by Apotex Corp.. Trabectedin is used to treat certain types of cancer. It is supplied as a injection, solution, concentrate for intravenous administration. This product entry covers the primary NDC 60505-6423 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 60505-6423?
What are the uses of this product?
What are Active Ingredients of this product?
- TRABECTEDIN .05 mg/mL - A complex structure that includes isoquinolines joined by a cyclic ester; it is a DNA-binding agent and guanine N2 alkylator derived from the marine tunicate, Ecteinascidia turbinata. Trabectedin is used for the treatment of advanced soft-tissue SARCOMA, after failure of ANTHRACYCLINES or IFOSFAMIDE drug therapy.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TRABECTEDIN (UNII: ID0YZQ2TCP)
- TRABECTEDIN (UNII: ID0YZQ2TCP) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- GLYCINE (UNII: TE7660XO1C)
- LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.